Immuneering Corporation
NASDAQ:IMRXBiotechnology
-$0.01 today
- Market cap
- $226.67M
- Beta
- 0.38
- P/E (TTM)
- -3.6
- EPS (TTM)
- -$1.24
Volume 0.73M
Average 1.38M
IMRX Total Equity
Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.
Immuneering CorporationNASDAQ: IMRX
Total Equity · Q1 FY2026 · quarter ended Mar 2026
Total equity rises 493455.8% from a year ago
Total equity stood at $206.52B at the end of Q1 FY2026, up 493455.8% from a year earlier and up 94423.3% from the prior quarter. Over 3 fiscal years it compounded at +25.8% a year.
Context
- Total equity amounted to 96.1% of total assets at the end of Q1 FY2026, up 13.6 pp from a year earlier.
- Total equity increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total equity keeps rising in the next quarterly balance sheet after a +493455.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Equity history
USD · from the balance sheet
- Latest · FY2025
- 218.48M USD
- Year-over-year change
- +427.9%
- 4-year CAGR
- +8.8%
| Period | Period end | Total Equity | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 218.48M | +427.9% |
| FY2024 | 2024-12-31 | 41.39M | -54.3% |
| FY2023 | 2023-12-31 | 90.58M | -17.5% |
| FY2022 | 2022-12-31 | 109.85M | -29.6% |
| FY2021 | 2021-12-31 | 155.98M | — |
Total Equity vs competitors
How IMRX compares with its peers on the latest reported figures
- IMRX's Mar 2026 total equity of $206.52B is the highest of the 11 companies compared; the peer median is $130.5M.
- Its year-over-year change of +493455.8% is the highest of 11, against a peer median of -21.0%.
- Total equity amounts to 96.1% of total assets for IMRX, versus a peer median of 78.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $206.52B | +493455.8% | +25.8% | 96.1% | |
| Mar 2026 | $270.85M | -35.1% | +12.9% | 80.7% | |
ZURAZura Bio Limited | Mar 2026 | $216.9M | +43.3% | — | 94.9% |
| Mar 2026 | $198.61M | +632.0% | +35.7% | 84.3% | |
| Mar 2026 | $191.36M | -18.1% | -7.5% | 78.0% | |
| Mar 2026 | $144.42M | -25.7% | -20.7% | 81.2% | |
| Mar 2026 | $116.59M | +24.6% | -41.4% | 37.0% | |
| Mar 2026 | $106.19M | -11.1% | -20.3% | 78.6% | |
| Mar 2026 | $31.27M | -69.7% | -30.8% | 48.6% | |
| Mar 2026 | $11.62M | -67.7% | -70.2% | 10.5% | |
| Mar 2026 | -$76.41M | -23.9% | — | 34.4% | |
| Peer median (excluding IMRX) | $130.5M | -21.0% | -20.5% | 78.3% | |
Competitors are the stored peer set for IMRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 74.89M | 72.64M | 59.41M | 36.14M | 128.65M |
| Short-term Investments | 74.31M | 32.89M | 26.26M | 0 | 44.19M |
| Net Receivables | 246.04K | 12.42K | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 3.21M | 3.42M | 3.44M | 3.41M |
| Total Current Assets | 152.33M | 108.75M | 89.08M | 39.59M | 176.25M |
| Property, Plant & Equipment (Net) | 6.13M | 5.78M | 5.4M | 4.79M | 4.26M |
| Goodwill | 6.7M | 6.69M | 6.69M | 6.69M | 6.69M |
| Intangible Assets | 439K | 408.95K | 379.68K | 350.41K | 321.15K |
| Long-term Investments | 996.56K | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 102.13K | 743.7K | 1.03M | 1.3M | 44.47M |
| Total Non-current Assets | 14.37M | 13.62M | 13.5M | 13.13M | 55.74M |
| Total Assets | 166.7M | 122.37M | 102.58M | 52.71M | 231.99M |
| Account Payables | 1.39M | 3.15M | 2.11M | 1.96M | 1.54M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 2.92M | 3.65M | 3.89M | 3.82M | 4.54M |
| Total Current Liabilities | 5.63M | 8.05M | 7.85M | 7.5M | 10.07M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 5.09M | 4.46M | 4.16M | 3.82M | 3.43M |
| Total Liabilities | 10.72M | 12.52M | 12.01M | 11.33M | 13.5M |
| Common Stock | 26.32K | 26.42K | 29.27K | 31.05K | 64.65K |
| Retained Earnings | (59.27M) | (109.79M) | (163.26M) | (224.3M) | (280.32M) |
| Accumulated OCI | (49.01K) | (30.12K) | (778) | 0 | 81.33K |
| Other Stockholders Equity | 0 | 0 | 0 | 1 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 155.98M | 109.85M | 90.58M | 41.39M | 218.48M |
| Total Debt | 5.36M | 4.84M | 4.46M | 4.16M | 3.82M |
| Net Debt | (69.52M) | (67.8M) | (54.94M) | (31.98M) | (124.82M) |
Immuneering Corporation
NASDAQ:IMRX
Intrinsic Alpha fair value
Locked
Current Price
$3.50
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.